Rep. Robert Bresnahan, Jr. Purchases Shares of Humana Inc. (NYSE:HUM)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Humana Inc. NYSE: HUM. In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Humana stock on February 25th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 3/7/2025.
• Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/6/2025.
• Purchased $1,001 - $15,000 in shares of SEA NYSE: SE on 3/5/2025.
• Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 3/4/2025.
• Sold $15,001 - $50,000 in shares of Alibaba Group NYSE: BABA on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Zoom Video Communications NASDAQ: ZM on 3/4/2025.
• Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 3/3/2025.
• Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/3/2025.

Humana Stock Performance

Shares of HUM stock traded down $1.57 on Wednesday, hitting $263.17. 457,951 shares of the stock were exchanged, compared to its average volume of 1,553,938. The firm's 50 day moving average is $269.37 and its two-hundred day moving average is $272.67. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The firm has a market capitalization of $31.76 billion, a PE ratio of 26.45, a P/E/G ratio of 2.05 and a beta of 0.57. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Sell-side analysts expect that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be issued a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a yield of 1.35%. The ex-dividend date of this dividend is Friday, March 28th. Humana's dividend payout ratio (DPR) is 35.58%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Cerity Partners LLC boosted its stake in Humana by 72.0% during the 3rd quarter. Cerity Partners LLC now owns 31,605 shares of the insurance provider's stock valued at $10,011,000 after purchasing an additional 13,233 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in shares of Humana by 12.2% during the 3rd quarter. Daiwa Securities Group Inc. now owns 14,762 shares of the insurance provider's stock valued at $4,676,000 after acquiring an additional 1,608 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of Humana during the third quarter valued at approximately $404,000. Independent Advisor Alliance raised its holdings in shares of Humana by 68.3% during the third quarter. Independent Advisor Alliance now owns 2,141 shares of the insurance provider's stock valued at $678,000 after purchasing an additional 869 shares during the last quarter. Finally, Bank of Montreal Can boosted its holdings in Humana by 18.4% in the third quarter. Bank of Montreal Can now owns 189,168 shares of the insurance provider's stock worth $60,452,000 after purchasing an additional 29,460 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.

Analysts Set New Price Targets

HUM has been the subject of a number of research analyst reports. Piper Sandler lifted their price objective on shares of Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a report on Wednesday, January 15th. Barclays lifted their price target on shares of Humana from $255.00 to $270.00 and gave the stock an "equal weight" rating in a research note on Thursday, February 13th. StockNews.com cut shares of Humana from a "buy" rating to a "hold" rating in a research report on Tuesday, March 18th. Royal Bank of Canada restated an "outperform" rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Finally, Truist Financial raised their price objective on Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research note on Monday, January 6th. Eighteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $285.68.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.